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Abstract 23	  
The atmospheric pressure chemical ionization (APCI) source for gas 24	  
chromatography-mass spectrometry analysis has been evaluated for the screening 25	  
of 16 exogenous androgenic anabolic steroids (AAS) in urine. The sample 26	  
treatment is based on the strategy currently applied in doping control laboratories 27	  
i.e. enzymatic hydrolysis, liquid-liquid extraction (LLE) and derivatization to form 28	  
the trimethylsilyl ether-trimethylsilyl enol ether (TMS) derivatives. These TMS 29	  
derivatives are then analyzed by gas chromatography tandem mass spectrometry 30	  
using a triple quadrupole instrument (GC-QqQ MS/MS) under selected reaction 31	  
monitoring (SRM) mode. The APCI promotes soft ionization with very little 32	  
fragmentation resulting, in most cases, in abundant [M+H]+ or [M+H-2TMSOH]+ 33	  
ions, which can be chosen as precursor ions for the SRM transitions, improving in 34	  
this way the selectivity and sensitivity of the method. Specificity of the transitions 35	  
is also of great relevance, as the presence of endogenous compounds can affect the 36	  
measurements when using the most abundant ions. The method has been 37	  
qualitatively validated by spiking six different urine samples at two concentration 38	  
levels each. Precision was generally satisfactory with RSD values below 25 and 15 39	  
% at the low and high concentration level, respectively. Most the limits of detection 40	  
(LOD) were below 0.5 ng mL -1. Validation results were compared with the 41	  
commonly used method based on the electron ionization (EI) source. EI analysis 42	  
was found to be slightly more repeatable whereas lower LODs were found for 43	  
APCI. In addition, the applicability of the developed method has been tested in 44	  
samples collected after the administration of 4-chloromethandienone. The highest 45	  
sensitivity of the APCI method for this compound, allowed to increase the period in 46	  
which its administration can be detected.  47	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1. Introduction   55	  
Since 2004, the World Anti-Doping Agency (WADA) publishes a list of prohibited 56	  
substances and methods in sport which is yearly updated [1]. Among the groups of 57	  
substances included in the list, androgenic anabolic steroids (AAS) are the most 58	  
frequently reported ones [2]. AAS are mainly used due to their anabolic effects 59	  
such as muscle and strength growth among others [3].  60	  
AAS are prohibited at all times i.e. in and out of competition. This prohibition 61	  
makes that any evidence of AAS misuse (e.g. the mere presence of traces of the 62	  
AAS and/or its metabolites) is sufficient for reporting an adverse analytical finding 63	  
[4]. The detection of AAS misuse is a constant analytical challenge due to their low 64	  
concentration in urine, the complexity of the matrix and the similarity between 65	  
endogenous and exogenous AAS. Thus, sensitivity and selectivity of analytical 66	  
methods are key factors and requirements for AAS detection have evolved hand in 67	  
hand with instrumental developments. 68	  
AAS have been traditionally determined by gas chromatography mass spectrometry 69	  
(GC-MS) methods working in selected ion monitoring mode (SIM) using electron 70	  
ionization (EI) sources [5]. After some preparation steps [6] i.e. hydrolysis with β-71	  
glucuronidase, liquid-liquid extraction and conversion of both hydroxyl and 72	  
carbonyl function into the corresponding TMS ether/enol-TMS ethers, these 73	  
methods allowed the detection of most of AAS metabolites at concentrations below 74	  
10 ng mL -1. For this reason, the minimum required performance level (MRPL) for 75	  
most AAS was set at 10 ng mL -1. However, these methods failed for the detection 76	  
of several AAS at the required MRPL, mainly those with difficulties in the 77	  
derivatization step. Among them, stanozolol and AAS bearing a 4,9,11-triene 78	  
nucleus like tetrahydrogestrinone (THG) [7].  79	  
The occurrence of high resolution mass spectrometry opened new possibilities for 80	  
the detection of stanozolol [8], although the scenario drastically changed after the 81	  
introduction of liquid chromatography tandem mass spectrometry (LC-MS(/MS)) in 82	  
doping control laboratories [9,10]. Several methods have been developed for the 83	  
LC-MS/MS detection of AAS with poor derivatization properties like stanozolol 84	  
and THG [11, 12, 13]. Thus, both GC-MS(/MS) and LC-MS(/MS)  have been 85	  
employed as complementary techniques in doping control laboratories in order to 86	  
reach the required MRPLs. Qualitative methods for the detection of exogenous 87	  
AAS in urine by LC-MS/MS with triple quadrupole (QqQ) analyzers and 88	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electrospray ionization source (ESI)  [11] have been reported, as well as GC-89	  
MS/MS methods with EI [14, 15] or chemical ionization (CI) sources [16]. 90	  
In the last years, the commercialization of triple quadrupole instruments coupled to 91	  
GC has allowed for increasing the sensitivity of the previous GC-MS methods. 92	  
Thus, several GC-EI-MS/MS methods in selected reaction monitoring mode (SRM) 93	  
have been published either for the detection of target analytes [14, 15] or for 94	  
metabolic studies [17, 18, 19]. Nowadays, this technique has become the gold-95	  
standard in AAS analysis for doping control purposes. Due to the sensitivity 96	  
improvement, the MRPL for AAS has been recently reduced to 2-5 ng mL -1 for 97	  
most analytes [4]. This fact illustrates the impact of new analytical technologies in 98	  
the detection of AAS. Therefore, it is valuable to test the performance of emerging 99	  
analytical tools in this field. 100	  
As an alternative to EI, different “soft” ionization sources for GC have been tested 101	  
for the detection of AAS in doping analysis, i.e. CI [16], heated nebulizer 102	  
microchip atmospheric pressure photoionization (µAPPI) [20, 21] or atmospheric 103	  
pressure chemical ionization (APCI) [22, 23]. The recently commercialized APCI 104	  
source for GC represents an attractive alternative in several application fields [24, 105	  
25, 26]. APCI promotes soft ionization for the generation of [M+H]+ or M+· ions as 106	  
the base peak of the spectrum, by means of protonation or charge transfer 107	  
mechanisms, deeper explained in literature [22, 27]. This soft ionization presents an 108	  
advantage in the selection of specific precursor ions in MS/MS based methods. 109	  
In the present work, the potential of APCI source using GC-MS/MS was evaluated 110	  
for the development of a screening method for the detection of selected exogenous 111	  
AAS in urine. After validation, the performance of the GC-APCI-MS/MS method 112	  
has been compared with the conventional GC-EI-MS/MS, by analyzing a group of 113	  
samples prepared under the same conditions. The applicability of the method was 114	  
also evaluated in a set of samples collected at different times after the 115	  
administration of 4-chloromethandienone (4Cl-MTD). 116	  
 117	  
  118	  
 119	  
120	  
	   5	  
2. Experimental 121	  
 122	  
2.1.  Chemical and reagents 123	  
The structures of the selected AAS are shown in Figure 1. Boldenone (BD) was 124	  
obtained from Sigma (St. Louis, MO, USA). 17β-hydroxy-5β-androstan-1-ene-3-125	  
one (Boldenone metabolite, BDmet), 17β-methyl-5β-androst-1-en-3α,17α-diol 126	  
(Methandienone metabolite, MTDmet3), 1-testosterone (1-T), 5α-androstan-17α-127	  
methyl-3α,17β-diol (Methyltestosterone metabolite, MeTmet1), 5β-androstan-17α-128	  
methyl-3α,17β-diol (Methyltestosterone metabolite, MeTmet2), 5β-androstan-129	  
7β,17α-dimethyl-3α,17β-diol (Calusterone metabolite, CALUSmet), 17α- metyl-1-130	  
testosterone (Me-1-T), 5β-androstan-7α,17α-dimethyl-3α,17β-diol (Bolasterone 131	  
metabolite, BOLASmet), 13β,17α-diethyl-5β-gonane-3α,17β-diol (Norbolethone 132	  
metabolite, NORBOLmet2) 6β-hydroxy-4-chloromethandienone (6OH-4Cl-MTD) 133	  
and 4-hydroxy-testosterone (4OH-T) were purchased from NMI (Pymble, 134	  
Australia). Fluoxymesterone (FLU) was obtained from Steraloids (Newport, RI, 135	  
USA). 5α-Androstan-2α,17α-dimethyl-3α,17β-diol (Methasterone metabolite, 136	  
METHASmet) was a kind gift from the World Association of Anti-Doping 137	  
Scientists (WAADS). Oxymesterone (OXY) and madol (MADOL) were provided 138	  
by the Toronto Research Chemicals (Toronto, Canada).  139	  
AAS stock standard solutions at 10 and 100 µg mL -1 in methanol were stored at -140	  
20 ºC. Working MIX solutions at appropriate concentration levels for validation 141	  
were prepared in acetone and also stored at -20 ºC, whereas individual standard 142	  
solutions were employed for the transition optimization step and for potential cross-143	  
talk evaluation. 144	  
β-glucuronidase solution (Escherichia coli, type K12) was purchased from Roche 145	  
Diagnostics (Mannheim, Germany). Analytical grade potassium carbonate, 146	  
potassium hydroxide pellets, sodium hydrogen phosphate, di-sodium hydrogen 147	  
phosphate, tert-butyl-methyl ether and ammonium iodide were acquired from 148	  
Merck (Darmstadt, Germany). The derivatization reagent preparation N-methyl-N-149	  
trimethylsilyl-trifluoroacetamide (MSTFA) was purchased from Karl Bucher 150	  
Chemische Fabrik GmbH (Waldstetten, Germany) and 2-mercaptoethanol from 151	  
Sigma-Aldrich (St Louis, MO, USA). Milli Q water was obtained using a Milli-Q 152	  
purification system (Millipore Ibérica, Barcelona, Spain). Formic acid and 153	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ammonium formate (LC/MS grade), acetonitrile and methanol (LC gradient grade) 154	  
were purchased from Merck (Darmstadt, Germany).  155	  
 156	  
 157	  
2.2.  Instrumentation 158	  
2.2.1. GC-APCI-MS/MS 159	  
An Agilent 7890A GC system (Palo Alto, CA, USA) equipped with an Agilent 160	  
7693 autosampler was coupled to a triple quadrupole mass spectrometer, Xevo TQ-161	  
S (Waters Corporation, Manchester, UK), using an APGC source, operating in 162	  
APCI mode. The GC separation was performed using an HP Ultra 1 capillary 163	  
column, (length 16 m × I.D. 0.20 mm × film thickness 0.11 µm). For the named as 164	  
gradient 1, the oven was programmed as follows: 185 °C (0.5 min); 25 °C min -1 to 165	  
230 °C; 10 °C min -1 to 290 °C; 70 ºC min -1 to 310 ºC (2.5 min), being the total run 166	  
time 11.6 min. Gradient 2 programme was: 180 ºC (1 min); 3 ºC min -1 to 230 ºC; 167	  
40 ºC min -1 to 310 ºC (3 min), total run time 22.7 min. Split injections (ratio 1:10) 168	  
of 2 µL using a straight deactivated liner with glass wool were carried out at 280 169	  
°C. Helium 99.999% (Carburos Metálicos, Spain) was used as carrier gas at 2 mL 170	  
min -1.  171	  
The interface temperature was set to 300 °C using N2 as auxiliary gas at 250 L h -1, 172	  
make up gas at 300 mL min -1, and cone gas at 170 L h -1. The temperature in the 173	  
source was set at 150 ºC. The APCI corona pin was operated at 1.55 µA and a cone 174	  
voltage of 20 V was selected. The water used as modifier when working under 175	  
proton-transfer conditions was placed in an uncapped vial, which was located 176	  
within a holder placed in the source door. For MS/MS measurement, argon 177	  
99.995% (Carburos Metálicos, Spain) was used as collision gas at a pressure of 178	  
4.15 × 10 −3 mbar in the collision cell (Table 1).  179	  
 180	  
2.2.2. GC-EI-MS/MS 181	  
For all EI experiments, a 7890A gas chromatograph equipped with a 7693 182	  
autosampler and coupled to a 7000A Series Triple Quadrupole GC/MS (Agilent 183	  
Technologies) was employed. The same column and chromatographic conditions 184	  
detailed in the APCI section (gradient 1) were used. 185	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Nitrogen was used as collision gas at a flow rate of 1.5 mL min -1, and helium 186	  
(Abello-Linde) as a quenching gas at a flow rate of 2.25 mL min -1. The electron 187	  
impact source was kept at 230 ºC and the quadrupoles at 150 ºC. 188	  
  189	  
2.3. Sample preparation  190	  
Urine samples were treated as previously described in literature [14, 15]. Briefly, 191	  
25 µL of internal standard solution (methyltestosterone, 10 µg mL -1) was added to 192	  
2.5 mL of urine. Then, the solution was hydrolyzed by the addition of 1 mL 193	  
phosphate buffer (pH 7) and 30 µL of β-glucuronidase solution (55 ºC, 1h). After 194	  
cooling at room temperature, 200 mg of NaHCO3/Na2CO3 buffer (1:2; w/w) was 195	  
added (pH 9.5). A LLE step was carried out by adding 6 mL of methyl tert-butyl 196	  
ether (MTBE). After centrifugation (4350 rpm, 5 min.), the organic phase was 197	  
separated and evaporated to dryness (45 ºC). Finally, in order to obtain the enol-198	  
trimethylsylil (TMS) derivatives of the analyte, 50 µL of a mixture of 199	  
MSTFA/NH4I/2-mercaptoethanol (1000/2/6; v/w/v) was added to the dry extract 200	  
and then kept at 60 °C for 20 min. 201	  
 202	  
2.4. Validation  203	  
Following the WADA criteria [4], the validation of the screening method was 204	  
designed in order to confirm the suitability of the method to detect half the MRPL 205	  
of the compound. The method validation was performed using spot urine samples 206	  
collected from six volunteers (three male and three female which did not take any 207	  
steroid). Two spiking levels were selected taking into account the current MRPL 208	  
for the compounds (Table 2). Low concentration levels (LCL) of 1 ng mL -1 and 2 209	  
ng mL -1, and high concentration levels (HCL) of 10 ng mL -1 and 20 ng mL -1 were 210	  
selected for AAS with MRPLs of 2 ng mL -1 and 5 ng mL -1, respectively. In this 211	  
sense, around 0.5xMRPL and 5xMRPL levels were assayed in both cases. 212	  
For the evaluation of the extraction recoveries of each analyte, six blank samples 213	  
were spiked at the high concentration level and extracted. The same samples were 214	  
extracted and spiked after the extraction. The extraction recovery was calculated by 215	  
comparing peak areas for each analyte in both cases.  216	  
Relative standard deviation (RSD) of the ratio between the peak areas of each 217	  
compound and the internal standard were calculated. Repeatability (expressed as 218	  
RSD) for each analyte was evaluated at the two concentration levels tested.  219	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Based on WADA suggestions [4], the limit of detection (LOD) for each analyte was 220	  
estimated as the concentration that produced a peak signal of three times the 221	  
background noise in the chromatogram at the lowest fortification level.  222	  
Selectivity was tested by analyzing 10 different blank urines and monitoring the 223	  
absence of interferences with signal to noise (S/N) ratios above 3.  224	  
 225	  
2.5. Application to real samples  226	  
To study the applicability of the validated method, samples from an excretion study 227	  
of 4-chloromethandienone (4Cl-MTD) were analyzed. A single dose of 20 mg of 228	  
4Cl-MTD (oral Turinabol) was administrated to a male volunteer (49 years, 85 kg) 229	  
and different urine samples at intervals of 0-4 h, 4-8 h, 8-12 h, 12-24 h, 24-36 h, 48-230	  
56 h and 72-84 h were collected.  231	  
The study was conducted in accordance with the Declaration of Helsinki. Subject 232	  
signed an informed consent before participation. Treatment was well tolerated by 233	  
the subjects and no serious adverse events were observed.  234	  
 235	  
3. Results and discussion 236	  
 237	  
3.1. Transition optimization 238	  
Two transitions were optimized for each compound to improve the reliability of the 239	  
method. The first step was the acquisition of a full scan spectrum for each 240	  
individual TMS-derivative standard. Once the main precursor ions were selected, 241	  
[M+H]+, [M+H-TMSOH]+ or [M+H-2TMSOH]+, depending on the structure of the 242	  
steroid [21], product ion spectra were obtained at different collision energies (10, 243	  
20, 30 and 40 eV) (Figure S1, supplementary information). Based on this 244	  
information, the largest number of possible optimized SRM transitions was 245	  
preselected. Then, ten blank urine extracts and ten extracts spiked at the LCL were 246	  
tested in order to choose the best transitions for each analyte in terms of sensitivity 247	  
and specificity. Transitions showing the maximum S/N and the minimum influence 248	  
of the background of the matrix interferences were selected.  249	  
For most analytes, the most sensitive transition was found to be specific enough 250	  
since matrix interferences were not observed. Therefore, it was selected for 251	  
detection of the compound in the screening. However, in some cases such as OXY, 252	  
(Figure S2, supplementary information), the selected transition was not the most 253	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abundant (535.2>269.2), because of the presence of matrix interferences. Thus, a 254	  
less sensitive but more specific transition was selected (535.2>389.5). In the case of 255	  
NORBOLmet2 and BD in APCI, it was not possible to select any specific transition 256	  
because of the presence of endogenous steroids with the same transitions at the 257	  
same retention times under the selected conditions.  258	  
A list of the selected SRM transitions used in APCI, facing EI ones, is summarized 259	  
in Table 1.  260	  
 261	  
3.2. Method validation 262	  
Table 2 summarizes the results obtained for extraction recovery, repeatability and 263	  
LOD by using GC-APCI-MS/MS. Suitable extraction recovery values between 67 264	  
and 89% were obtained in all cases except for Me-1-T (47%) and BDmet (53%).  265	  
Repeatability was evaluated by the RSD at both LCL and HCL (n=6 for each level). 266	  
Values between 3% and 30% were obtained confirming the satisfactory precision of 267	  
the method. As expected, better repeatability was observed at the HCL, being in 268	  
most cases below 15%, except for 6OH-4Cl-MTD (RSD 22%).  269	  
In terms of selectivity, no interferences were detected in the ten blank samples for 270	  
the transitions selected for each compound. Regarding LOD, most of them were 271	  
lower than 0.5 ng mL -1 and always below the established MRPL (Table 2). As 272	  
stated in the previous section the main exceptions for this behaviour were 273	  
NORBOLmet2 and BD, which were interfered by the presence of matrix 274	  
components irrespective of the selected transition. Chromatographic separation was 275	  
found to be critical for the proper validation of these compounds. The use of a 276	  
longer gradient (gradient 2 in the experimental section) allowed for the 277	  
discrimination between analytes and the matrix interferences (Figure S3, 278	  
supplementary information). Using this gradient all analytes were adequately 279	  
validated. In order to isolate as much as possible the effect of the interface, results 280	  
using gradient 1 will be discussed. Only in the case of NORBOLmet2 and BD 281	  
results for gradient 2 are discussed. 282	  
It is well-known that, differently to EI, atmospheric pressure ionization is more 283	  
affected by matrix constituents that lead to possible matrix-induced 284	  
suppression/enhancement of the analytes ionization. Since the main goal of the 285	  
developed method was not  quantification of the analytes but the 286	  
detection/identification of all selected AAS at the LCL,, this effect was not 287	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evaluated as that qualitative objective was satisfactorily reached independently on 288	  
the matrix effects that might affect to ionization. However, matrix effect may be 289	  
behind the higher RSD observed in APCI and it should be evaluated if the purpose 290	  
of the analyses was quantification of analytes.  291	  
Figure 2 shows typical chromatograms obtained for a blank urine sample compared 292	  
with those of a sample spiked at the LCL. 293	  
 294	  
3.3. Comparison APCI vs EI 295	  
In order to evaluate the performance of the developed GC-APCI-MS/MS method, 296	  
the validation results were compared with those obtained by GC-EI-MS/MS. All 297	  
the factors involving the detection (urine used, extraction, derivatization, column 298	  
and gradient of temperatures) were controlled in order to isolate as much as 299	  
possible the effect of the ionization source. Ideally, both sources should be coupled 300	  
to the same analyzer. Unfortunately, this ideal situation is currently not affordable, 301	  
i.e. both interfaces are not interchangeable, and, therefore, every source was 302	  
coupled to a different QqQ analyzer. Thus, although the discussion will be focused 303	  
on the effect of the interface, a potential influence of the specific analyzer on the 304	  
results cannot be discarded. 305	  
Validation results for both methodologies are shown in Table 2. Regarding 306	  
repeatability, in general, RSD values were lower for EI. At LCL, RSDs ranged 307	  
from 0.6% to 14% in EI whereas in APCI increased up to 3.2-18%. At HCL, RSDs 308	  
in the range 0.3-5% and 3-14% were obtained for EI and APCI, respectively. Some 309	  
values higher than 20 were punctually obtained. Thus, although RSDs from both 310	  
studies can be considered acceptable, a slightly better repeatability of the EI source 311	  
was found in this study. The lower repeatability of APCI might be due either to 312	  
factors affecting the ionization process such as the amount of water in the interface 313	  
or to the potential matrix effect suffered by APCI.  314	  
Regarding sensitivity, the results largely depended on the MS behaviour of the 315	  
steroid. Thus, analytes with an abundant [M+H]+ in APCI (BDmet, 1-T, Me-1-T, 316	  
4OH-T, FLU, 6OH-4Cl-MTD, BD and OXY exhibited LODs in the sub-ng/mL 317	  
range (below 0.4 ng/mL) i.e. more than 10 times lower than the current MRPL for 318	  
most AAS. For these AAS, LODs estimated for APCI were between 5 and 20 times 319	  
lower than for EI (Figure 3a), even in those cases in which an abundant M+· was 320	  
also present in EI.  321	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Worse LODs (typically between 0.3 and 1 ng/mL) were obtained for AAS showing 322	  
an abundant [M+H-nTMSOH]+ in APCI (MADOL, MTDmet3, MeTmet1, 323	  
CALUSmet, MeTmet2, METHASmet, NORBOLmet2 and BOLASmet). For these 324	  
compounds, LODs using APCI were commonly in the same range as those obtained 325	  
by EI (Table 2, Figure 3b). The low specificity of the product ions can be behind 326	  
this fact. After the in-source neutral loss of all TMS present in the molecule (lost as 327	  
TMSOH), the remained hydrocarbon skeleton was selected as precursor ion. Under 328	  
these conditions the selection of a specific product ion was troublesome. Thus, most 329	  
of the product ions obtained was not specific and both matrix interferences and high 330	  
background decreased the sensitivity of the method. Only for BOLASmet, a 331	  
specific product ion (m/z 175) could be obtained. In this case, the sensitivity was 332	  
similar to those AAS exhibiting a [M+H]+.  333	  
The selection of abundant and specific precursor ions was a key factor when aiming 334	  
at the maximum sensitivity. In the light of obtained results, it is noteworthy to 335	  
mention that the presence of [M+H]+ in APCI led to the best results in terms of 336	  
sensitivity. Future work in the search of diverse derivatizing agents that maximize 337	  
the protonated molecule in APCI would be valuable. 338	  
 339	  
3.4. Application to real samples 340	  
To check the applicability of the developed methodology, samples collected after 341	  
4Cl-MTD administration were analyzed by GC-APCI-MS/MS and the results were 342	  
compared with those obtained by GC-EI-MS/MS.  343	  
As expected, the main metabolite of 4-chloromethandienone (6OH-4Cl-MTD) was 344	  
detected by both methods in the urines collected during the first hours after 345	  
administration (Figure 4a). Owing the better sensitivity provided by APCI, the 346	  
misuse of 4Cl-MTD could be detected in samples in which the metabolite was 347	  
undetectable by the commonly used GC-EI-MS/MS methods (Figure 4b). 348	  
Therefore, the period of time in which the misuse can be detectable increased from 349	  
56 h to 84 h (the last sample collected) by using APCI. This fact illustrates the 350	  
potential and future of this source in the detection of AAS misuse. 351	  
 352	  
4. Conclusions 353	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The suitability of GC-APCI-MS/MS for sensitive detection of AAS has been 354	  
demonstrated by the validation of a method for the detection of 16 exogenous AAS 355	  
in urine.  356	  
The present work illustrates the potential of the new APCI source as an adequate 357	  
alternative to the traditional EI source in GC-MS methodologies. Due to the 358	  
endogenous steroids present in urine, the selection of a specific transition has been 359	  
found to be a key factor in the method development. Optimization of the 360	  
chromatography was found to be critical for the correct detection of two of the 361	  
analytes (BD and NORBOLmet2). Although suitable precision (RSD values below 362	  
25 and 15% at LCL and HCL, respectively) was obtained with the APCI method, it 363	  
was slightly higher than the one obtained with EI.  364	  
Sensitivity was found to be higher with APCI for the majority of compounds tested, 365	  
with LODs commonly lower than 0.5 ng mL -1. These LODs are similar to the 366	  
obtained with other soft ionization sources like CI [16]. The higher sensitivity 367	  
obtained can be related with the abundance of a specific product ion. This, in 368	  
around 50% of the analytes, the soft ionization of provided by the APCI source 369	  
allowed for the selection of the [M+H]+ as precursor ion. In the rest of analytes, 370	  
ions resulting from one or two losses of TMSOH from the derivatizing reagent 371	  
were selected as precursor. These ions keep still the steroidal skeleton helping in 372	  
the selection of specific product ions.  373	  
Anyway, the presence of an abundant [M+H]+ in the mass spectra and its selection 374	  
as precursor ion was found to be related with a higher sensitivity. Since the selected 375	  
derivative (TMS) does not favor the protonation, the use of derivatives with higher 376	  
proton affinity would theoretically improve the sensitivity of the method. Further 377	  
research in order to investigate the applicability of other derivatizing agents able to 378	  
generate specific fragments would be desirable. 379	  
The notable improvement in sensitivity provided by the use of APCI source in GC-380	  
MS/MS methods is of great relevance in doping control field, as revealed in the 381	  
application of the method for the detection of 4-chloromethandienone misuse. 382	  
Therefore, the use of GC-(APCI) MS/MS based methods could increase the period 383	  
of time in which the misuse of the AAS can be detected, and opens interesting 384	  
possibilities in the near future. 385	  
 386	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FIGURE CAPTIONS 498	  
Figure 1.- Structures of the selected analytes. 499	  
Figure 2.- APCI optimized transitions of selected AAS in (a) blank urine sample 500	  
and (b) urine sample spiked at LCL. 501	  
Figure 3.- Comparison between APCI and EI for selected compounds: (a) BDmet 502	  
and (b) MADOL.  503	  
Figure 4.- Comparison between APCI and EI in urine samples collected after 504	  
administration of 4Cl-MTD. Chromatograms of samples collected between (a) 24-505	  
36 h after administration and (b) 72-84 h after administration.	  506	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Figure 2. 531	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Figure 3.	   535	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Figure 4. 540	  
 APCI EI 
(a) 
4ClMTD_C009U021 (5)
Time
6.50 7.00 7.50 8.00
%
0
100
ABUSA0918 18: MRM of 3 Channels AP+ 
495.1 > 315.1 (4Cl Methandienone met)
1.31e7
 
+ MRM (315.1 -> 227.1) 4CL-Methandienona_21.D  Smooth
Acquisition Time (min)
7.9 8 8.1
3x10
0
0.5
1
1.5
C
o
u
n
ts
 
(b) 
4ClMTD_C009U023 (7)
Time
6.50 7.00 7.50 8.00
%
0
100
ABUSA0920 18: MRM of 3 Channels AP+ 
495.1 > 315.1 (4Cl Methandienone met)
4.71e6
 
+ MRM (315.1 -> 227.1) 4CL-Methandienona_23.D  Smooth
Acquisition Time (min)
8 8.1
2
x10
0
1
2
3
C
o
u
n
ts
7.9  
 541	  
 542	  
543	  
	  
	  
	   24	  
TABLES 544	  
Table 1.- Selected acquisition conditions for the SRM method for both GC-APCI-545	  
MS/MS and GC-EI-MS/MS. 546	  
  
Analyte 
  
Derivative 
  
Mw [M+H]+ 
APCI EI 
 RT 
(min) Transition 
CE 
(eV) 
 RT 
(min) Transition 
CE 
(eV) 
MADOL mono-O-TMS 361 3.96 
271.1>105.1* 30 
4.49 
345.3>201.1 15 
271.1>90.9 30 345.3>255.1 15 
BDmet bis-O-TMS 433 4.27 
433>417* 10 
4.73 
432.4>194.1 14 
433>187 20 432.4>206.1 14 
MTDmet3 bis-O-TMS 449 4.27 
269>201* 10 
4.74 
358.3>301.3 12 
269>105 30 358.3>196.1 12 
1-T bis-O-TMS 433 5.03 
343.2>179.1* 20 
5.61 
432.4>194.1 15 
433.3>417 20 432.4>207.2 15 
MeTmet2 bis-O-TMS 451 5.07 
271.2>215.2* 10 
5.64 
270.2>213.2 15 
361.2>271.1 10 270.2>199.1 15 
MeTmet1 bis-O-TMS 451 5.08 
271.2>215.2* 20 
5.64 
255.2>199.1 25 
361.3>255.2 20 255.2>159.1 25 
METHASmet bis-O-TMS 465 5.25 
285.2>229.2* 20 
5.84 
449.4>269.2 19 
375.3>245.2 20 449.4>213.2 19 
BD bis-O-TMS 431 5.29 
341.2>193.1* 20 
5.86 
430.4>206.2 18 
431.3>193.1 20 430.4>191.2 30 
CALUSmet bis-O-TMS 465 5.32 
285.3>109* 20 
5.91 
284.2>227.2 15 
285.3>175 20 374.3>269.2 13 
BOLASmet bis-O-TMS 465 5.49 
285.2>175.1* 20 
6.08 
284.2>227.2 15 
375.2>245.2 20 284.2>269.2 15 
Me-1-T bis-O-TMS 447 5.52 
357.2>179.2* 20 
6.14 
446.4>194.1 20 
447.3>431.3 20 446.4>143.1 20 
NORBOLmet2 bis-O-TMS 465 5.97 
375.3>285.2* 10 
6.61 
435.4>255.2 12 
375.3>231.2 20 435.4>345.3 12 
4OH-T tris-O-TMS 521 6.40 
431.3>296.2* 30 
7.08 
520.4>147.1 33 
521.3>405.3 40 505.4>147.1 10 
FLU tris-O-TMS 553 6.82 
463.3>297.4* 30 
7.52 
552.4>462.4 20 
553.3>353.4 20 552.4>319.3 20 
OXY tris-O-TMS 535 6.91 
535.2>389.5* 20 
7.62 
534.4>429.4 30 
535.2>269.2 30 389.3286.2 30 
6OH-4Cl-
MTD bis-O-TMS 495 7.25 
495.1>315.1* 10 
7.99 
315.1>227.1 20 
495.1>155 40 315.1>241.1 15 
* Most specific transition 547	  
548	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Table 2.- Validation parameters obtained for extraction recovery (n=6), 549	  
repeatability and LOD for APCI and EI analysis.  550	  
 
Analyte 
Current 
MRPL 
(ng mL-1) 
Extraction 
recovery 
(%) 
LCL 
(ng mL-
1) 
Repeatability 
(%) HCL  
(ng mL-1) 
Repeatability  
(%) 
LOD 
(ng mL-1) 
APCI EI APCI EI APCI EI 
MADOL 5 75 2 10 1 20 6 0.3 1 1 
BDmet 5 53 2 30 14 20 4.8 5.3 0.1 0.5 
MTDmet3 2 70 1 5.3 1.2 10 4.6 0.5 0.3 0.3 
1-T 5 79 2 4.2 2.5 20 14 0.5 0.3 2 
MeTmet2 2 85 1 4.8 2.3 10 3.9 0.4 0.3 0.5 
MeTmet1 2 83 1 12 2.7 10 6.3 1 0.5 0.5 
METHASmet 5 78 2 24 8.5 20 9.1 2.3 1 0.3 
BD* 5 89 2 3.8 2.5 20 5.9 2 0.1 1 
CALUSmet 5 76 2 18 2.3 20 3.5 2 1 2 
BOLASmet 5 80 2 23 5.2 20 6.8 1.6 0.1 1 
Me-1-T 5 47 2 9.7 5.4 20 4.9 5.1 0.3 1 
NORBOLmet2* 5 71 2 13 0.6 20 7.7 1.3 0.4 2 
4OH-T 5 68 2 9.4 2.4 20 4.6 1.1 0.4 2 
FLU 5 73 2 25 21 20 4 2.3 0.1 1 
OXY 5 71 2 13 27 20 3 1.4 0.5 1 
6OH-4Cl-MTD 2 86 1 3.2 4.2 10 22 0.3 0.2 1 
* APCI values for BD and NORBOLmet2 were calculated using gradient 2 (see experimental section) 551	  
 552	  
